ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic treatment offers only modest survival benefits in previously treated metastatic gastroesophageal adenocarcinoma (GEA). Treatment monitoring using imaging-based response assessments are often delayed and imprecise, highlighting the need for biomarkers to guide early treatment decisions. We evaluated the value of circulating tumor DNA (ctDNA) for prognosis, patient selection, and on-treatment monitoring in patients with previously treated GEA.
methodsThis retrospective study aimed to investigate whether baseline ctDNA levels and early ctDNA changes assessed by ctDNA-RECIST were associated with survival outcomes in a randomized Phase 2 trial comparing trifluridine-tipiracil plus bevacizumab or trifluridine-tipiracil alone. Plasma samples were collected at baseline and during treatment (weeks 4 and 8). ctDNA was quantified by a tumor-agnostic methylation-specific digital droplet PCR (ddPCR) assay.
resultsPlasma samples were available in 86 patients out of a total of 103 patients included in the trial. Patients with the highest baseline ctDNA levels (top 20%, n = 18) had significantly shorter progression-free survival (PFS; median 1.8 vs. 4.6 months; HR 2.2, p = 0.005) and overall survival (OS; median 5.5 vs. 9.9 months; HR 2.2, p = 0.004) compared to those with lower levels. Early progression by ctDNA at four weeks (HR 2.4, p = 0.003) and at eight weeks by radiological assessment (HR 2.9, p = 0.001) were both associated with inferior OS.
conclusionsctDNA is a strong prognostic biomarker in refractory GEA. High baseline levels and early increases identify patients unlikely to benefit from treatment. Prospective validation is needed, but ctDNA monitoring may enable earlier therapeutic decision-making in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.